



박 형 준

연세의대

Genomic analysis in neurologic diseases

Hyung Jun Park

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine

- We are in an unprecedented era of hope for therapies for DMD based on the underlying molecular basis of the disease.

Katharine Bushby et al. Lancet Neurol 2010



Variant nomenclature



- *CAPN3*, NM_000070.2, c.1468C>T(p.Arg490Trp)



- *CAPN3*, NM_000070.2, c.1468C>T(p.Arg490Trp)

Gene symbol
: Homo sapiens=> DNA 명은 모두 italic체로

Ex) *CAPN3*: Homo sapiens
Capn3: mus musculus
capn3: Zebra fish



- *CAPN3*, NM_000070.2, c.1468C>T(p.Arg490Trp)

Reference sequence

- : 여러 개의 transcript 중 대표적인 sequence
- ⇒ 일반적으로 가장 큰 transcript를 기준
- ⇒ 많은 경우 transcript 1이나 아닌 경우도 많음.
- ⇒ 각각 유전자에 대한 DATABASE에서 확인가능

Published in final edited form as:
Neurogenet (2014) 18(2):147-157

ONE myopathy: new name

Marjan Huisman¹, Maria Camillo-Castelli², Stella Miran-Rosenbaum³,
¹NeuroGenetics Branch, National Health, Bethesda, Maryland, USA

²Transcript for Rare and Neglected Diseases, National Institutes of Health, Department of Neurological Research, Neurology and Psychiatry, Tokyo, Japan

³Genetics Section, Institute of Gene Therapy, Jerusalem, Israel

⁴Department of Neurology, Helsinki, Finland

Received 10/10/2013; revised 11/10/2013; accepted 11/10/2013

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Copyright © 2014 Society for Neuroscience 0270-6474/14/34147-11\$15.00/0

This article is freely available online at: www.jneurosci.org

DOI:10.1523/JNEUROSCI.4511-13.2014

Genomic analysis

- MLPA method: large deletion과 duplication을 정량화하여 보여줌

- Duchenne muscular dystrophy의 *DMD* gene
- spinal muscular dystrophy의 *SMN1* gene
- CMT1A의 *PMP22* duplication/deletion

- Direct sequencing

- 일반적인 missense, nonsense, splicing site, small del/in의 확인에 사용
- 일반적으로 말하는 유전자검사

- 두 방식은 서로 보완적으로 원인 유전자의 흔한 돌연변이 유형에 따라 서로 시퀀싱이 다르다.


- Ex) DMD: MLPA
- ABCD1: Direct sequencing => MLPA

- Next generation sequencing의 적용

- *CAPN3*, NM_000070.2, c.1468C>T(p.Arg490Trp)

Start codon으로부터 exon의 염기서열순서를 표기

- c.1468C>T: start codon ATG의 A를 1로 할 때 1468번째 염기가 원래 C(cytosine)인데 T(thymine)로 치환
- p.Arg490Trp: start codon Met를 1로 할 때 490째 아미노산이 원래 Arg(arginine)인데 T(tryptophan)로 치환



ALD, ABCD1 gene

[Result]

상기환자의 ABCD1 (ATP-binding cassette, sub-family D, member 1) gene에 대한 염기서열 분석결과 돌연변이가 검출되지 않았습니다.

• Human Genome Mutation Database (<http://www.hgmd.org>)

Gene	Exon	Nucleotide change	Amino acid change	Mutation Effect
ABCD1	-	-	-	-

[Test Information]

1. Specimen: Genomic DNA isolated from peripheral blood leukocyte

2. Target gene: ABCD1

3. Chromosomal Location: Xq28

4. OMIM: #300100 for disease; *300371 for gene

GeneBank accession number: U71996.1; NM_000033.3

본 결과는 PCR-Sequencing방법으로 ALD환자의 약 6% 정도에서는 한계이상 Exon의 duplication이나 deletion에 의해 유발되는데 본 검사법(PCR-Sequencing)으로는 검출이 불가능하므로 임상적으로 의심되시면 추가검사사항(ex. MLPA)을 받으실바랍니다.

Genomic analysis

- MLPA method: large deletion과 duplication을 정량화하여 보여줌

- Duchenne muscular dystrophy의 *DMD* gene
- spinal muscular dystrophy의 *SMN1* gene
- CMT1A의 *PMP22* duplication/deletion

- Direct sequencing

- 일반적인 missense, nonsense, splicing site, small del/in의 확인에 사용
- 일반적으로 말하는 유전자검사

- 두 방식은 서로 보완적으로 원인 유전자의 흔한 돌연변이 유형에 따라 서로 시퀀싱이 다르다.

- Ex) DMD: MLPA
- ABCD1: Direct sequencing => MLPA

- Next generation sequencing의 적용


유선형근이영양증, 안면어깨상관근이영양증, 근긴장근이영양증

MLPA방법, D4Z4반복수분석, CUG 삼중기 반복분석

CMT1A/HNPP, 척수성근위축증


Classical Heber-Beck Disease, MLPA방법

Sanger's sequencing




Sanger's sequencing

- Sequencing can be performed on RT-PCR derived cDNA from muscle RNA, or on genomic DNA.
- Complex rearrangements, or variants located deep into the large introns of the gene will not be detected.




Copy number variation



- Available tests**
- MLPA(multiplex ligation-dependent probe amplification)
 - MAPH(multiplex amplification and probe hybridization)
 - CGH array (comparative genomic hybridization array)


MLPA (multiplex ligation-dependent probe amplification)



PCR + Southern blotting

- Trinucleotide repeats

- Cut DNA using Restriction endonucleases
- Electrophoresis on an agarose gel to separate them by size
- Move the DNA from the gel onto the nitrocellulose (or, alternatively, nylon) membrane
- Expose to a hybridization probe which is labelled so that it can be detected
- After hybridization, the pattern of hybridization is visualized on X-ray film by autoradiography in the case of a radioactive or fluorescent probe




유형	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)	유전자형 (Genotype)
Linkage analysis (autosomal STRs)	0	0	0	0	0	0	0	0	0
FISH	0	0	0	0	0	0	0	0	0
Array CGH or virtual karyotyping	0	0	0	0	0	0	0	0	0
Genome-wide SNP microarray	0	0	0	0	0	0	0	0	0
Targeted PCR	0	0	0	0	0	0	0	0	0
Sanger's sequencing	0	0	0	0	0	0	0	0	0
Southern blot or MLPA	0	0	0	0	0	0	0	0	0
Partial or pathway sequencing	0	0	0	0	0	0	0	0	0
WGS or WGA	0	0	0	0	0	0	0	0	0

CGH: 비교유전체분석법(comparative genomic hybridization), FISH: 형광중소배합법(fluorescent in situ hybridization), MLPA: 다중염색체복합증(multiplex ligation-dependent probe amplification), SNP: 단일염색체다형성(single-nucleotide polymorphism), STR: 단가달달반복(short tandem repeat), WES: 전체엑솜열기서열분석(whole-exome sequencing), 전체유전체열기서열분석(whole-genome sequencing)

Known point mutation

• Sanger sequencing

Ex) Hot-spot 있는 경우, Validation, 가족검사



c.640G>T variant in *GSN*



Copy number variation

- 형광동소조합법(fluorescence in situ hybridization; FISH)
- 단일염기다형성어레이 (SNP array)
- 비교유전체조합법(array comparative genomic hybridization; aCGH)
- 실시간중합효소연쇄반응(real-time polymerase chain reaction)
- 서던블롯검사(Southern blotting)
- 다발중합효소연쇄반응(multiplex polymerase chain reaction)
- 다중증폭프로브교배법(multiplex amplifiable probe hybridization, MAPH)
- 다중결찰의존프로브증폭법(multiplex ligation-dependent probe amplification, MLPA)
- 차세대염기서열 분석법(next-generation sequencing; NGS)



Trinucleotide repeat disease

• 반복의 크기가 작은 경우

- 헌팅턴병(Huntington disease)
- 중합효소연쇄반응(polymerase chain reaction, PCR)
+ 모세관 전기영동법(capillary electrophoresis)

• 반복의 크기가 큰 경우

- Myotonic dystrophy
- 서던블롯(Southern blot)



Many targeted genes

- Next-generation sequencing
(Massive parallel sequencing)




Sanger's sequencing vs NGS


- 클론(clone)을 얻는 과정을 단순화
- 대량 병렬(massively parallel)방식
- 염기서열분석방법이 다름



Next-generation sequencing



Application of Next-generation sequencing



Limitation of conventional approach




Next-generation sequencing - limitation

- 한 번에 읽을 수 있는 염기서열이 150 base pair로 제한적임
 - 반복염기가 많거나 GC 함량이 높아지면 error율이 증가
 - Trinucleotide repeat 또는 large duplication/deletion과 같이 정량적 분석이 필요한 원인유전자의 진단은 어려움
- Intron 영역에 대한 해석을 위한 방법이 제한적임.



Deletion of exon 45-47



Whole-exome vs Whole-genome

	Whole-exome	Whole-genome
Depth	High	Low
Interpretation	Easy	Difficult
Handling	Easy	Difficult
Copy number variation	Possible	Relatively accurate

Molecular diagnosis of WES was rendered for 2076 of 7374 patients (28.2%).



Diagnostic ratio of WGS: 41%

Official Journal of the American College of Medical Genetics and Genomics

ORIGINAL RESEARCH ARTICLE

Genetics
in Medicine

Open

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Results: Genetic testing in 100 patients with idiopathic congenital deafness comprised of 168 genes. Standard of care offers a time-consuming and expensive approach to genetic testing. We used a targeted gene sequencing panel, which has only 50 genes and is more affordable. Whole-genome sequencing (WGS) provided a comprehensive testing approach, but is not available in a clinical setting. We found that we can limit our targeted approach to 168 genes in clinical use.

Methods: We prospectively recruited 100 patients from pediatric otitis media with effusion (OME) and congenital deafness. We tested for suggestive of an underlying genetic disorder, and compared the depth and coverage of WGS with those of conventional genetic testing.

Results: WGS identified genetic variants at 41% of individuals, compared to 28% for targeted testing. The depth of coverage was 30x for WGS (24% $\geq 80\times$). Genetic clinically sequencing in the cohort ($n = 123$) were well covered by WGS, with a maximum coverage of 402x $\geq 80\times$ (mean $\geq 50\times$). At the molecular level, we found 100% coverage for 168 genes. The WGS approach identified 18 new diagnoses made with WGS included structural and non-coding sequence variants not detectable with whole-exome sequencing. We found 100% coverage of the 168 genes with the gene panel: RPL19, MYO15A, TMC1, and USH1C.

Conclusion: WGS as a primary clinical test provided a higher depth of coverage for conventional genetic testing in a clinically heterogeneous cohort.

Genet Med advance online publication 3 August 2017

Keywords: qPCR; number variation; non-coding sequence; sequencing; targeted; diagnostic; whole-genome sequencing


Govet Mail advance online publication 3 August 2017

Key Words: copy number variation, next-generation sequencing, uncoding, diagnostics, whole-genome sequencing

Genet Med 2018; 20(4): 435–443



Our previous targeted sequencing



We identified 93 (36%) patients with pathogenic/likely pathogenic variants.

Park HJ et al. Clin Genet 2017;91:403-410




Experience in our institution

- Targeted sequencing for about 400 neuromuscular-associated genes
- **Diagnostic ratio:** 43.5% (128 of 294)



Long-read whole genome sequencing

- LRS allows for the retrieval of much longer (>10,000bp) sequencing reads than widely-used SRS systems (75-300bp).
- Read lengths of 10,000- 100,000bp are more common.



Variant and pathogenicity

ACMG STANDARDS AND GUIDELINES

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards, PhD¹, Nazneen Aziz, PhD^{2,16}, Sherri Bale, PhD¹, David Bick, MD⁶, Soma Das, PhD¹, Julie Gastier-Foster, PhD^{6,7,8}, Wayne W. Grody, MD, PhD^{9,10,11}, Madhuri Hegde, PhD¹², Elaine Lyon, PhD¹³, Elaine Spector, PhD¹⁴, Karl Voelkerling, MD¹³ and Heidi L. Rehm, PhD¹⁵; on behalf of the ACMG Laboratory Quality Assurance Committee

Database

[illegible]

Database

gnomAD
genome aggregation database

gnomAD v2.1.1 Search by gene, region, or variant

Please note that gnomAD v2.1.1 and all earlier legacy non-overlapping samples and built datasets must be used to capture the full set of variation across gnomAD. For more information, see the FAQ. (Scroll to the bottom section of gnomAD)

Example: Gene: PCOLCE, Variant: 1:105118865G>A

HOVAD home page
The Human Gene Mutation Database
at the Institute of Medical Genetics to Cardiff

HGMD Home Search Help Statistics Site About What's New Downloads Publications Contact Us Login Other Links

Gene symbol: Missense/nonsens: Go!

Leiden Muscular Dystrophy pages®
Center for Human and Clinical Genetics,
Leiden University Medical Center

YONSEI UNIVERSITY

Type of variants

Missense mutation
Original DNA code for an amino acid sequence
DNA: CATCATCATCATCATCATCAT
Amino acid: Histidine
Replacement of a single nucleotide
DNA: CATCATCATCATCATCATCAT
Amino acid: Isoleucine
Insertion of a single nucleotide, which may produce a malfunctioning protein.

Nonsense mutation
Original DNA code for an amino acid sequence
DNA: CAGCAGCAGCAGCAGCAGCAG
Amino acid: Glutamine
Replacement of a single nucleotide
DNA: CAGCAGCAGCAGCAGCAGCAG
Amino acid: Stop
Insertion of a single nucleotide, which may produce a malfunctioning protein.

Small frameshift deletion
DNA: CATCATCATCATCATCATCAT
Amino acid: Histidine
Deletion of a single nucleotide
DNA: CATCATCATCATCATCATCAT
Amino acid: Isoleucine
Insertion of a single nucleotide, which may lead to production of a malfunctioning protein.

Insertion
DNA: CATCATCATCATCATCATCAT
Amino acid: Histidine
Insertion of a single nucleotide
DNA: CATCATCATCATCATCATCAT
Amino acid: Isoleucine
Insertion of a single nucleotide, which may produce a malfunctioning protein.

YONSEI UNIVERSITY

Type of variants

Splicing variants

Splice donor site: A C A G G U P u A G U
Branch site: C U P u A P y
Splice acceptor site: P y r i c h N C A G G e

20 - 50 bases

Intron

YONSEI UNIVERSITY

Inheritance	Protein Fx	Mutation
Dominant trait	Gain of function	Missense
	Dominant negative effect	Nonsense
	Haploinsufficiency	Frameshift
	Loss of function	Duplication / Deletion
Recessive trait		

YONSEI UNIVERSITY

Protein Fx

Gain of function
Dominant negative effect
Haploinsufficiency
Loss of function

단백질의 양이 증가하면서 증상을 일으킴
Ex) *PMP22* duplication in CMT1A

손상된 단백질이 쌓이면서 증상을 일으킴
Ex) *Myotilin* in Myofibrillar myopathy

(c) Gain-of-function mutation (M)

YONSEI UNIVERSITY

Protein Fx


Gain of function
Dominant negative effect
Haploinsufficiency
Loss of function

(a) Null loss-of-function mutation (m)

단백질 양이 감소하여서 증상이 나타남
Ex) *SMN1* in spinal muscular atrophy

일반적으로 50%이상의 단백질손실이 있어야 증상이 나타남 그렇지 않은 경우를 Haploinsufficiency라고 일컬음.
Ex) channelopathy

YONSEI UNIVERSITY



Heterogeneity in phenotype-genotype relationship

- Progressive external ophthalmoplegia를 일으키는 *POLG1* mutation은 autosomal dominant와 autosomal recessive로 모두 유전된다.
- COL6A1*, *COL6A2*, *COL6A3*는 autosomal dominant일 경우 mild Bethlem myopathy로 autosomal recessive일 경우 severe Ullrich congenital muscular dystrophy로 ...

=> Phenotype 및 Genotype이 다르다.

In-silico analysis

Category	Name	Website	Notes
Sequence prediction	Clustal	http://www.ebi.ac.uk/Tools/seqtools/online/clustal.html	Sequence alignment
	EMBOSS	http://www.ebi.ac.uk/Tools/seqtools/online/emboss.html	Sequence alignment
	MAFFT	http://mafft.cbrc.jp/alignment/software/	Sequence alignment
	MEGA	http://www.megasoftware.net/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
	PhyML	http://phylml.org/	Sequence alignment
Sequence prediction	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction
	GeneMark	http://www.ebi.ac.uk/Tools/seqtools/online/gemmark.html	Sequence prediction

Summary

- Variant nomenclature
- Point variant vs Copy number variation vs Trinucleotide repeat
- Variant vs Pathogenicity
- Massively palliative sequencing